A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Miller, Walter J ^a   Kayton, Mark L ^a   Patton, Angela ^b   O'Connor, Sarah ^a   He, Mei ^a   Vu, Huan ^a   Baibakov, Galina ^c   Lorang, Dominique ^a   Knezevic, Vladimir ^c   Kohn, Elise ^b   Alexander, H Richard ^a   Stirling, David ^d   Payvandi, Faribourz ^d   Muller, George W ^d   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c 20/20 GeneSystems Inc   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

Angiogenesis; Chorioallantoic membrane (CAM); Confocal microscopy; Layered Expression Scanning (LES); XTT assay

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANIMAL CELL; ARTICLE; BIOASSAY; CAPILLARY DENSITY; CELL PROLIFERATION; CHICKEN; CHORIOALLANTOIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; EMBRYO; ENDOTHELIUM CELL; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 4344663950     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-4     Document Type: Article

References (21)

1. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in-vivo by dominant-negative Flk-1mutant. Nature 1994, 367:576-579.
2. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in-vivo. Nature 1993, 362:841-844.
3. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995, 13:765-782.
4. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A Randomized trial of bevacizumab, an antivascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
5. Giantonio BJ, Levy D, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson B: Bevacizumab (anti-VEGF) plus IFL irinotecan, fluorouracil. leucovorin) as front line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. ASCO 2003., 1024:
6. Toi M: Endothelial growth factors: Target of antiangiogenesis, Ovarian Cancer Research notebook. The Cancer Journal 2003, 8:1-7.
7. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther 1994, 63:265-311.
8. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N: Angiogenesis assays: a critical overview. Clin Chem 2003, 49:32-40.
9. Ribatti D, Vacca A, Roncali L, Dammacco F: The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol 2000, 1:73-82.
10. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990, 348:555-557.
11. Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, Ogura Y: Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci 1999, 40:2690-2696.
12. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO: Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci 2000, 6:6427-6432.
13. Wang J, Lou P, Henkin J: Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000, 77:465-73.
14. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A: Methionine aminopeptidase-2 regulates human mesothelioma cell survival: Role of Bcl-2 expression and telomerase activity. Am J Path 2001, 159:721-731.
15. Brooks PC, Montgomery AM, Cheresh DA: Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol 1999, 129:257-69.
16. Zhang LH: Novel potent class of small molecules, inhibitors of tubulin polymerization and TNF-a production with anti-tumor activity. Proc Amer Assoc Cancer Res2 Edition 2003, 44:LB-22.
17. Englert CR, Baibakov GV, Emmert-Buck MR: Layered expression scanning: rapid molecular profiling of tumor samples. Cancer Res 2000, 60:1526-1530.
18. Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR: Post-analysis follow-up and validation of microarray experiments. Nature Genet 2002, 32:509-514.
19. Suzuki E, Nishimatsu H, Nagata D, Satonaka H, Goto A, Omata M, Fujita T, Nagai R, Hirata Y: Constitutive activation of proto-oncogen protein p21 induces cell cycle arrest in the G1 phase in contact-inhibited vascular endothelial cells. Hypertens Res 2002, 25:773-778.
20. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997, 4:461-471.
21. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci 1997, 94:6099-6103.